Clinical Trials Logo

Perimenopausal Bone Loss clinical trials

View clinical trials related to Perimenopausal Bone Loss.

Filter by:
  • None
  • Page 1

NCT ID: NCT04942691 Completed - Clinical trials for Postmenopausal Osteopenia

Prevention of Osteoporosis: Effects of Mini-trampoline Training on the Bone Remodeling

TRAMBONE
Start date: September 1, 2019
Phase: N/A
Study type: Interventional

The aim of the project is to study the effects on bone remodeling induced by training carried out with the trampoline in order to evaluate the reduction of the resorption itself and therefore the onset of osteoporosis in women.

NCT ID: NCT00290212 Completed - Clinical trials for Perimenopausal Bone Loss

Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause

Start date: January 2006
Phase: Phase 2
Study type: Interventional

Study Objective: To determine whether Natto supplementation in women immediately after menopause might prevent severe bone loss Study population: Women 50 - 60 years, 1-5 years after menopause Study Design: Double-blind, placebo-controlled, randomized controlled trial. A "phase II" clinical trial. Instruments Used to Measure Therapeutic Response: Lunar Prodigy DEXA bone densitometer Study Treatment Group: Daily supplementation with Vitamin K2, "NATTO" Study Control Group: Identically-looking placebo medication Duration of treatment: 12 months Duration of Subject Participation in Study: 12 months Assessment of Therapeutic response: Given an expected reduction of bone mass density of - 1.1% annually in the placebo group, the minimum clinically significant difference between the groups is 0.3 percentage points. The trial is therefore powered to detect a reduction in annual bone mass loss of 0.3 percentage points in the treatment group. Numbers of Evaluable Subjects Required: 304 Maximum # Subjects 334

NCT ID: NCT00221312 Completed - Clinical trials for Perimenopausal Bone Loss

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

Start date: May 2002
Phase: N/A
Study type: Observational

This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause (perimenopausal transition). During the three to five years prior to the menopause, the rate of bone loss increases. One way that physicians treat this is with oral contraceptive medication. However, the incidence of complications from oral contraceptives after the age of 40 increases. Therefore, a non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a class of compounds called bisphosphonates. This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition.